trial · primary record
Lazertinib
Advanced or Metastatic Non-small Cell Lung Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 418 |
| Primary completion | 2027-06-30 |
| Primary endpoint | For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State |
| Registry ID | NCT05388669 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:36.397Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05388669
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Lazertinib · compound